AstraZeneca Gets CDSCO Panel Nod to Study anticancer drug Volrustomig
New Delhi: The drug major AstraZeneca has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the study of the anticancer drug Volrustomig (MEDI5752). This came after the drug maker AstraZeneca presented phase III clinical study protocol No. D798EC00001. This is a global study of […]